Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

PARP1 体内 替莫唑胺 血脑屏障 药理学 PARP抑制剂 癌症研究 体外 胶质瘤 医学 聚ADP核糖聚合酶 生物 内科学 DNA 生物化学 中枢神经系统 生物技术 聚合酶
作者
Anna D. Staniszewska,Domenic Pilger,Sonja J. Gill,Kunzah Jamal,Natacha Bohin,Sofia Guzzetti,Jacob Gordon,Gregory Hamm,Gill Mundin,Giuditta Illuzzi,Andy Pike,Lisa McWilliams,Gareth Maglennon,Jonathan Rose,Glen Hawthorne,Miguel A. Cortés González,Christer Halldin,Peter Johnström,Magnus Schou,Susan E. Critchlow
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:30 (7): 1338-1351 被引量:61
标识
DOI:10.1158/1078-0432.ccr-23-2094
摘要

PURPOSE: We evaluated the properties and activity of AZD9574, a blood-brain barrier (BBB) penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in combination with temozolomide (TMZ) in preclinical models. EXPERIMENTAL DESIGN: AZD9574 was interrogated in vitro for selectivity, PARylation inhibition, PARP-DNA trapping, the ability to cross the BBB, and the potential to inhibit cancer cell proliferation. In vivo efficacy was determined using subcutaneous as well as intracranial mouse xenograft models. Mouse, rat, and monkey were used to assess AZD9574 BBB penetration and rat models were used to evaluate potential hematotoxicity for AZD9574 monotherapy and the TMZ combination. RESULTS: AZD9574 demonstrated PARP1-selectivity in fluorescence anisotropy, PARylation, and PARP-DNA trapping assays and in vivo experiments demonstrated BBB penetration. AZD9574 showed potent single agent efficacy in preclinical models with homologous recombination repair deficiency in vitro and in vivo. In an O6-methylguanine-DNA methyltransferase (MGMT)-methylated orthotopic glioma model, AZD9574 in combination with TMZ was superior in extending the survival of tumor-bearing mice compared with TMZ alone. CONCLUSIONS: The combination of three key features-PARP1 selectivity, PARP1 trapping profile, and high central nervous system penetration in a single molecule-supports the development of AZD9574 as the best-in-class PARP inhibitor for the treatment of primary and secondary brain tumors. As documented by in vitro and in vivo studies, AZD9574 shows robust anticancer efficacy as a single agent as well as in combination with TMZ. AZD9574 is currently in a phase I trial (NCT05417594). See related commentary by Lynce and Lin, p. 1217.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
依古比古完成签到,获得积分10
1秒前
戒骄戒躁完成签到,获得积分10
1秒前
1秒前
与闲发布了新的文献求助10
1秒前
cdercder的应助被中雨采纳,获得10
1秒前
1秒前
Aresskaka完成签到,获得积分10
2秒前
2秒前
小马甲的应助被阳光采纳,获得10
2秒前
luoling发布了新的文献求助10
2秒前
十月的天空完成签到,获得积分10
3秒前
3秒前
经竺的应助被轻松蘑菇采纳,获得10
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
soleil完成签到,获得积分10
4秒前
贾克斯完成签到,获得积分20
5秒前
子夜歌发布了新的文献求助30
5秒前
贪玩以蓝发布了新的文献求助20
6秒前
文献搜集者完成签到,获得积分10
6秒前
hucai完成签到,获得积分10
6秒前
陈勇杰发布了新的文献求助10
6秒前
6秒前
科研民工发布了新的文献求助10
7秒前
深情安青的应助被坚强馒头采纳,获得30
7秒前
英姑的应助被遇见一只鹿采纳,获得10
7秒前
7秒前
7秒前
7秒前
MOCHEN发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187006
求助须知:如何正确求助?哪些是违规求助? 9575262
关于积分的说明 21840460
捐赠科研通 7784748
什么是DOI,文献DOI怎么找? 3434903
关于科研通互助平台的介绍 2559301
邀请新用户注册赠送积分活动 2481765